The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.
 
Neil Howard Segal
Consulting or Advisory Role - ABL Bio; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Numab; PureTech; Revitope
Research Funding - AstraZeneca; Bristol-Myers Squibb; Immunocore; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); Codiak Biosciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Gritstone Bio (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); OncXerna Therapeutics (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Eugenia Girda
No Relationships to Disclose
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; SOTERIA Precision Medicine; Sutro Biopharma
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Innovent Biologics; Janssen Oncology; Merck; Nutcracker Therapeutics, Inc.; RAPT Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; Pfizer; Sanofi; Takeda
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Hyunsil Han
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Kerry A. Casey
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Siyu Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Erik Welf
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Chieh-I Chen
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Dimitris Skokos
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Frank A. Seebach
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Melissa Divya Mathias
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Nehal J. Lakhani
Consulting or Advisory Role - Ikena Oncology; Innovent Biologics; SK Life Sciences
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Formation Biologics (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics; Innovent Biologics (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)